How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease?

被引:18
作者
Carta, Anna R.
Pinna, Annalisa
Morelli, Micaela
机构
[1] Univ Cagliari, Dept Toxicol, I-09124 Cagliari, Italy
[2] Univ Cagliari, Ctr Excellence Neurobiol Dependence, I-09124 Cagliari, Italy
[3] CNR, Inst Neurosci, Sect Cagliari, Cagliari, Italy
来源
BEHAVIOURAL PHARMACOLOGY | 2006年 / 17卷 / 5-6期
关键词
abnormal and involuntary movements; animal model; context; dopamine receptor; dyskinesia; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Parkinson's disease; primate; rat turning behaviour; 6-hydroxydopamine;
D O I
10.1097/00008877-200609000-00005
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
In spite of the current availability of several pharmacological therapies for the treatment of Parkinson's disease, side effects are invariably manifested during long-term treatment Dyskinesia, wearing-off and on-off are among the most disabling side effects produced by the dopamine precursor L-dihydroxyphenylalanine and, to a lesser degree, by other pharmacological treatments based on dopamine receptor agonism. Evaluation of the side effects, in particular dyskinesia, produced by antiparkinsonian drug treatments, therefore represents a critical issue in drug validation prior to a clinical trial. Moreover, a reliable model of dyskinesia is a fundamental requirement for the study of the as yet unknown mechanisms at the basis of this severely disabling side effect. The present review aims to provide a critical evaluation of the validity, reliability and utility of animal models of dyskinesia. In the first part of this review, we present a brief overview of the different models of Parkinson's disease focusing on those utilized for the evaluation of dyskinetic movements, then proceed to critically examine the turning behaviour model in an attempt to assess the way in which it has influenced the evaluation of drugs utilized in the treatment of Parkinson's disease. Subsequently, the various models of dyskinesia are reviewed and conclusions are drawn as to how the environment in which experiments are performed can influence the behaviour observed.
引用
收藏
页码:393 / 402
页数:10
相关论文
共 95 条
[1]   Striatal fosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease [J].
Andersson, M ;
Hilbertson, A ;
Cenci, MA .
NEUROBIOLOGY OF DISEASE, 1999, 6 (06) :461-474
[2]  
ASIN KE, 1995, J PHARMACOL EXP THER, V273, P1483
[3]  
BAUNEZ C, 1995, J NEUROSCI, V15, P6531
[4]  
BEDARD PJ, 1993, ADV NEUROL, V60, P113
[5]   CHRONIC TREATMENT WITH L-DOPA, BUT NOT BROMOCRIPTINE INDUCES DYSKINESIA IN MPTP-PARKINSONIAN MONKEYS - CORRELATION WITH [H-3] SPIPERONE BINDING [J].
BEDARD, PJ ;
DIPAOLO, T ;
FALARDEAU, P ;
BOUCHER, R .
BRAIN RESEARCH, 1986, 379 (02) :294-299
[6]   REVERSAL OF EXPERIMENTAL PARKINSONISM BY LESIONS OF THE SUBTHALAMIC NUCLEUS [J].
BERGMAN, H ;
WICHMANN, T ;
DELONG, MR .
SCIENCE, 1990, 249 (4975) :1436-1438
[7]   Chronic systemic pesticide exposure reproduces features of Parkinson's disease [J].
Betarbet, R ;
Sherer, TB ;
MacKenzie, G ;
Garcia-Osuna, M ;
Panov, AV ;
Greenamyre, JT .
NATURE NEUROSCIENCE, 2000, 3 (12) :1301-1306
[8]   Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates [J].
Bibbiani, F ;
Costantini, LC ;
Patel, R ;
Chase, TN .
EXPERIMENTAL NEUROLOGY, 2005, 192 (01) :73-78
[9]  
Blanchet PJ, 1995, J NEURAL TRANSM-SUPP, P103
[10]   Effects of L-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey [J].
Boraud, T ;
Bezard, E ;
Guehl, D ;
Bioulac, B ;
Gross, C .
BRAIN RESEARCH, 1998, 787 (01) :157-160